News Markets & Companies
H.B. Fuller board rejects unsolicited bid
H.B. Fuller’s board of directors has unanimously rejected a non-binding acquisition proposal from investment firm Ancora for its Building Adhesives Solutions (BAS) business, citing significant undervaluation, missing financial details, and strong growth prospects for the segment.
The proposed acquisition price of EUR 0.95 billion to USD 1.03 billion was a central point of contention. The board concluded that this figure “is substantially below precedent transactions and doesn’t represent full value for the business.” In addition, the board found that the proposal “lacks detail on its ability to finance the transaction or operate BAS without continuous support from the Company.”
Growth momentum and operational integration cited as key factors
Beyond valuation concerns, the board highlighted the BAS segment’s recent performance as a reason for its rejection. In the second quarter, BAS delivered organic growth of 6 % year-over-year and a 10 % EBITDA improvement. The board expects the segment to be “a significant driver of earnings moving forward” as construction end markets recover and benefit from tailwinds including data centre construction activity.
The board also pointed to deep operational integration as a further obstacle to any carve-out. The BAS business shares manufacturing infrastructure with H.B. Fuller’s other operations across more than 30 plants worldwide. According to the board’s assessment, separating the segment “would result in material operating inefficiencies,” with tax and other dis-synergies largely offsetting any benefits from debt reduction.
Strategic priorities and deleveraging on track
H.B. Fuller’s board reaffirmed its commitment to its current strategic agenda, which includes closing and integrating the acquisition of Advanced Medical Solutions, as well as advancing its internal restructuring programme, referred to as Project Quantum Leap. The latter involves continued footprint rationalisation and is expected to deliver a “step change in the earnings power of BAS over the near-term.”
On the question of leverage, the board expressed confidence in the company’s ability to bring its debt ratio back within a target range of 2.5x to 3.0x within two years of completing the Advanced Medical Solutions transaction, citing strong cash flow generation. The board stated it “regularly reviews the Company’s portfolio with an emphasis on maximising shareholder value” and will continue to evaluate all business units accordingly.
